Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
<p>Supplemental Figure S1. Mean pharmacokinetic profiles for single agent talazoparib (BMN673 in phase I clinical trial PRP-001) versus combination therapy.</p>
Sábháilte in:
| Príomhchruthaitheoir: | |
|---|---|
| Rannpháirtithe: | , , , , , , , , , , , , , , |
| Foilsithe / Cruthaithe: |
2025
|
| Ábhair: | |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
| _version_ | 1849927633769332736 |
|---|---|
| author | Zev A. Wainberg (15047031) |
| author2 | Arun S. Singh (15036660) Gottfried E. Konecny (15047034) Kelly E. McCann (15047037) J. Randolph Hecht (15047040) Jonathan Goldman (15047043) Bartosz Chmielowski (15036666) Richard S. Finn (10431048) Neil O'Brien (15047046) Erika Von Euw (15047049) Megan M. Price (15047052) Diego Martinez (15047055) Lisa Yonemoto (15047058) Meghan Brennan (15047061) John A. Glaspy (15047064) Dennis J. Slamon (15047067) |
| author2_role | author author author author author author author author author author author author author author author |
| author_facet | Zev A. Wainberg (15047031) Arun S. Singh (15036660) Gottfried E. Konecny (15047034) Kelly E. McCann (15047037) J. Randolph Hecht (15047040) Jonathan Goldman (15047043) Bartosz Chmielowski (15036666) Richard S. Finn (10431048) Neil O'Brien (15047046) Erika Von Euw (15047049) Megan M. Price (15047052) Diego Martinez (15047055) Lisa Yonemoto (15047058) Meghan Brennan (15047061) John A. Glaspy (15047064) Dennis J. Slamon (15047067) |
| author_role | author |
| dc.creator.none.fl_str_mv | Zev A. Wainberg (15047031) Arun S. Singh (15036660) Gottfried E. Konecny (15047034) Kelly E. McCann (15047037) J. Randolph Hecht (15047040) Jonathan Goldman (15047043) Bartosz Chmielowski (15036666) Richard S. Finn (10431048) Neil O'Brien (15047046) Erika Von Euw (15047049) Megan M. Price (15047052) Diego Martinez (15047055) Lisa Yonemoto (15047058) Meghan Brennan (15047061) John A. Glaspy (15047064) Dennis J. Slamon (15047067) |
| dc.date.none.fl_str_mv | 2025-11-25T12:48:39Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30706476 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplemental_Figure_S1_from_Preclinical_and_Clinical_Trial_Results_Using_Talazoparib_and_Low-Dose_Chemotherapy/30706476 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Clinical Trial Results Phase I clinical trials Drug Targets Oncoprotein & tumor suppressor drug targets Preclinical Models In vitro models of cancer |
| dc.title.none.fl_str_mv | Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Supplemental Figure S1. Mean pharmacokinetic profiles for single agent talazoparib (BMN673 in phase I clinical trial PRP-001) versus combination therapy.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_bb89e07ab7f438c59d32b855b3b0c248 |
| identifier_str_mv | 10.1158/1078-0432.30706476 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30706476 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose ChemotherapyZev A. Wainberg (15047031)Arun S. Singh (15036660)Gottfried E. Konecny (15047034)Kelly E. McCann (15047037)J. Randolph Hecht (15047040)Jonathan Goldman (15047043)Bartosz Chmielowski (15036666)Richard S. Finn (10431048)Neil O'Brien (15047046)Erika Von Euw (15047049)Megan M. Price (15047052)Diego Martinez (15047055)Lisa Yonemoto (15047058)Meghan Brennan (15047061)John A. Glaspy (15047064)Dennis J. Slamon (15047067)CancerTherapeutic Research and DevelopmentClinical Research and TrialsMethods and TechnologyClinical Trial ResultsPhase I clinical trialsDrug TargetsOncoprotein & tumor suppressor drug targetsPreclinical ModelsIn vitro models of cancer<p>Supplemental Figure S1. Mean pharmacokinetic profiles for single agent talazoparib (BMN673 in phase I clinical trial PRP-001) versus combination therapy.</p>2025-11-25T12:48:39ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30706476https://figshare.com/articles/figure/Supplemental_Figure_S1_from_Preclinical_and_Clinical_Trial_Results_Using_Talazoparib_and_Low-Dose_Chemotherapy/30706476CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307064762025-11-25T12:48:39Z |
| spellingShingle | Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy Zev A. Wainberg (15047031) Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Clinical Trial Results Phase I clinical trials Drug Targets Oncoprotein & tumor suppressor drug targets Preclinical Models In vitro models of cancer |
| status_str | publishedVersion |
| title | Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy |
| title_full | Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy |
| title_fullStr | Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy |
| title_full_unstemmed | Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy |
| title_short | Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy |
| title_sort | Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy |
| topic | Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Clinical Trial Results Phase I clinical trials Drug Targets Oncoprotein & tumor suppressor drug targets Preclinical Models In vitro models of cancer |